Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006
September 8, 2015 4:01 PM EDTFX006 provides substantial and persistent pain relief compared to placebo; well-tolerated with safety profile comparable to placebo
Conference call scheduled for tomorrow, September 9, 2015, at 9:00 a.m. ET
BURLINGTON, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided)... More
Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006
September 8, 2015 4:01 PM EDTFX006 provides substantial and persistent pain relief compared to placebo; well-tolerated with safety profile comparable to placebo
Conference call scheduled for tomorrow, September 9, 2015, at 9:00 a.m. ET
BURLINGTON, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided)... More
